文献速递肿瘤 PET/CT核素与放射性配体治疗

[89Zr]Zr-阿替利珠单抗免疫PET用于转移性三阴性乳腺癌PD-L1定量的可行性

Feasibility of [89Zr]Zr-Atezolizumab Immuno-PET for PD-L1 Quantification in the Clinical Work-up of Metastatic Triple-Negative Breast Cancer.
PubMed 文献 · J Nucl Med · 2026-05-01

该研究评估[89Zr]Zr-阿替利珠单抗免疫PET/CT在转移性三阴性乳腺癌(mTNBC)PD-L1定量中的临床可行性。3例mTNBC患者接受免疫PET/CT后对靶病灶活检,若免疫组化或PET显示PD-L1阳性则接受阿替利珠单抗联合化疗。所有患者PET均见示踪剂摄取病灶,3例活检病灶中2例免疫组化为PD-L1阴性,存在个体内摄取异质性;所有患者治疗后均显示初始缓解。

要点

  • 3例mTNBC患者中,免疫PET均显示示踪剂摄取阳性病灶。
  • 3例活检的摄取阳性病灶中2例免疫组化PD-L1阴性,提示PET与免疫组化结果可不一致。
  • 所有患者接受阿替利珠单抗联合化疗后均显示初始缓解。

核心结论

  • [89Zr]Zr-阿替利珠单抗免疫PET用于mTNBC临床检查是可行的。
  • 该分子影像策略有潜力作为无创工具更准确地识别可能从免疫检查点抑制剂治疗中获益的mTNBC患者。

研究设计与样本

  • 研究纳入3例mTNBC患者,先接受[89Zr]Zr-阿替利珠单抗PET/CT,随后对靶转移病灶进行活检。
  • 若转移病灶免疫组化或PET成像显示PD-L1阳性,患者接受阿替利珠单抗联合化疗。

主要发现

  • 所有患者PET均显示示踪剂摄取的转移病灶。
  • 3例活检的示踪剂摄取病灶中2例免疫组化为PD-L1阴性。
  • 观察到个体内示踪剂摄取异质性。
  • 所有患者接受阿替利珠单抗联合化疗,均显示初始缓解。

关键数值与推荐

  • PD-L1阳性判定条件为转移病灶免疫组化或PET成像任一显示PD-L1阳性。

临床怎么用

  • 在mTNBC临床检查中可考虑[89Zr]Zr-阿替利珠单抗免疫PET/CT评估PD-L1状态。
  • PET显示示踪剂摄取阳性的转移病灶仍应结合活检免疫组化结果综合判断PD-L1状态。

局限性

  • 研究仅纳入3例患者,样本量小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune checkpoint inhibitors combined with chemotherapy are established as first-line therapy for patients with programmed death ligand 1 (PD-L1)-positive metastatic triple-negative breast cancer (mTNBC). We evaluated whether immuno-PET using [89Zr]Zr-atezolizumab could more accurately identify patients with mTNBC who may benefit from immune checkpoint inhibitor therapy. Methods: Three patients with mTNBC underwent [89Zr]Zr-atezolizumab PET/CT followed by a biopsy of a targeted metastatic lesion. Patients received atezolizumab plus chemotherapy if either immunohistochemistry of the metastatic lesion or PET imaging showed PD-L1 positivity. Results: All patients had tracer-avid metastatic lesions on PET. Two of 3 biopsied, tracer-avid lesions were PD-L1 negative on immunohistochemistry. Intraindividual heterogeneity in tracer uptake was noted. All patients were treated with atezolizumab plus chemotherapy, with all demonstrating an initial response. Conclusion: A work-up with [89Zr]Zr-atezolizumab immuno-PET is clinically feasible. This molecular imaging-based strategy holds potential as a noninvasive tool to more accurately identify patients with mTNBC who may benefit from immune checkpoint inhibitor therapy.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Nijveldt JJ, Af Burén S, Tran TA, et al. Feasibility of [89Zr]Zr-Atezolizumab Immuno-PET for PD-L1 Quantification in the Clinical Work-up of Metastatic Triple-Negative Breast Cancer. J Nucl Med. 2026. PMID: 41611476. doi:10.2967/jnumed.125.271459

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。